Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 11,161 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort study Clear all
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

NCT06447662
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

Penclomedine in Treating Patients With Solid Tumors or Lymphoma

NCT00002946
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
penclomedine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

NCT05065970
View directory record Official record
Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
Felzartamab, Placebo
Drug · Other
Lead sponsor
HI-Bio, A Biogen Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Not yet recruiting Not applicable Interventional

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

NCT06816979
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging
Procedure · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Moderate to Severe Refractory Crohn's Disease

NCT06721962
View directory record Official record
Conditions
Crohns Disease
Interventions
TRX103, Cyclophosphamide
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 30, 2026, 1:43 PM EDT
Terminated No phase listed Observational

Comparing Immune Responses to Topical Imiquimod

NCT04809662
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Imiquimod
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 30, 2026, 1:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III

NCT00439569
View directory record Official record
Conditions
Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III
Interventions
sodium phenylbutyrate
Drug
Lead sponsor
Westat
Other
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Stanford, California • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

NCT06609005
View directory record Official record
Conditions
Advanced Metastatic Castration Resistant Prostate Cancer
Interventions
INV-9956
Drug
Lead sponsor
Shenzhen Ionova Life Sciences Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Scottsdale, Arizona • Newport Beach, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Dexamethasone, Montelukast, Methotrexate, Amivantamab, Lazertinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Fountain Valley, California • Fairfax, Virginia • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

NCT02598960
View directory record Official record
Conditions
Solid Tumors
Interventions
BMS-986156, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 30, 2026, 1:43 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

64Cu-LLP2A for Imaging Multiple Myeloma

NCT03804424
View directory record Official record
Conditions
Multiple Myeloma
Interventions
64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT
Drug · Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Phase 2 Interventional

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

NCT04991103
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
DaraVRD/DaraVCD
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 30, 2026, 1:43 PM EDT
Active, not recruiting Phase 1 Interventional

Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

NCT03549442
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Carbon Fiber Implants

NCT03382041
View directory record Official record
Conditions
Tibial Shaft Fractures
Interventions
Carbon Fiber Implant, Titanium Implant
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 30, 2026, 1:43 PM EDT
Not listed No phase listed Observational

The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation

NCT05012605
View directory record Official record
Conditions
Stroke, Sleep Wake Disorders, Rehabilitation, Recovery of Function
Interventions
Observation
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Timeline
2021 – 2025
U.S. locations
6
States / cities
Atlanta, Georgia • Kansas City, Kansas • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4178256 in Healthy Participants

NCT07698210
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY4178256, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Alamitos, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Outcomes of a Small Process Group on Medical Students' Grit, Resilience, and Stress

NCT06003920
View directory record Official record
Conditions
Stress
Interventions
Process group
Behavioral
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Not applicable Interventional

GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health)

NCT06356220
View directory record Official record
Conditions
Celiac Disease in Children, Nutrition Disorder, Child
Interventions
Gluten-Free Diet Education
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Completed No phase listed Observational Results available

A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

NCT01077323
View directory record Official record
Conditions
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
Interventions
exenatide, Other antidiabetic therapies, No diabetes therapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
363,766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stress Free UCR: The Impact of 8 Weeks of Headspace on Stress in a Heterogeneous University Employee Cohort

NCT03695627
View directory record Official record
Conditions
Stress, Psychological
Interventions
Meditation
Behavioral
Lead sponsor
University of California, Riverside
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

NCT00942305
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Brincidofovir, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating Public Health Interventions to Improve COVID-19 Testing Among Underserved Populations

NCT05270694
View directory record Official record
Conditions
COVID-19
Interventions
Public Health Intervention Package
Behavioral
Lead sponsor
Kathleen Fairfield
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 30, 2026, 1:43 PM EDT